Name: 글로벌 시장 동향
SKU: MD2383
Availability: InStock

보고서 요약(국문)

세계 기관지 확장제 시장 개요
세계 기관지 확장제 시장 규모는 2022년 426억 4,987만 달러였으며, 2030년까지 663억 1,400만 달러에 이를 것으로 예상됩니다. 예측 기간(2023~2030년) 동안 연평균 성장률(CAGR)은 5.9%입니다.
기관지 확장제는 폐의 기관지를 확장시켜 근육을 이완시키는 데 사용되는 약물입니다. 이 약물은 공기가 폐로 드나들 수 있도록 해줍니다. 기관지 확장제는 폐에서 점액을 줄이는 데 효과적입니다. 이러한 약물은 천식 및 만성 폐쇄성 폐질환(COPD)과 같은 만성 질환 치료에 사용됩니다.

기관지 확장제는 폐의 점액을 줄이는 데 효과적입니다. 세계 기관지 확장제 시장 동향
기관지 확장제 시장은 흡연, 담배 소비 등 생활 습관 변화로 인한 만성 폐쇄성 폐질환(COPD) 및 천식 유병률 증가에 힘입어 성장하고 있습니다.
기술 발전과 만성 폐쇄성 폐질환 유병률 증가는 시장 성장을 견인할 것으로 예상됩니다.
만성 폐쇄성 폐질환(COPD)은 호흡곤란을 유발하고 악화 및 심각한 질병으로 이어질 수 있는 진행성 폐질환으로, 생명을 위협하는 질환입니다. 세계보건기구(WHO)에 따르면 2019년 전 세계적으로 약 2억 5천 1백만 명이 만성 폐쇄성 폐질환(COPD)을 앓고 있습니다. 전 세계적으로 만성 폐쇄성 폐질환(COPD)으로 인해 약 323만 명이 사망했습니다.
신규 기관지 확장제 승인 건수 증가는 시장 성장을 촉진할 것입니다. 2019년 4월, 서카시아(Circassia)는 COPD 치료제인 두아클리르(Duaklir)의 승인을 받았습니다. 두아클리르는 아클리디늄 브로마이드(400mcg)와 포모테롤 푸마르산염(12mcg)이라는 두 가지 장기 작용 기관지 확장제의 복합제입니다.
기관지 확장제 개발을 위한 연구 개발 활동의 증가와 신제품 출시가 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 베로나 파마(Verona Pharma plc)는 흡입형 이중 억제제인 엔시펜트린(ensifentrine)을 개발하고 있는데, 이는 단일 화합물에 포스포디에스테라제 3 및 4 효소 억제제, 기관지 확장제, 항염증제를 모두 함유하고 있는 최초의 신약 후보 물질입니다. 그러나 떨림, 신경 긴장, 심계항진, 근육 경련 등과 같은 기관지 확장제 관련 부작용은 시장 성장을 저해합니다.
기관지 확장제 관련 부작용은 시장 성장을 저해할 것으로 예상됩니다.
떨림, 신경 긴장, 심계항진, 근육 경련 등과 같은 기관지 확장제 관련 부작용은 시장 성장을 저해합니다.
글로벌 기관지 확장제 시장 - 산업 분석
글로벌 기관지 확장제 시장은 포터의 5가지 경쟁력 분석, 규제 분석, 공급망 분석, 가격 분석, 제품 혁신, 미충족 수요 등 다양한 산업 요인을 기반으로 시장에 대한 심층 분석을 제공합니다.

세계 기관지 확장제 시장 - 세그먼트 분석
약물 유형 세그먼트가 세계 기관지 확장제 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
기관지 확장제 시장은 약물 유형에 따라 교감신경흥분제, 항콜린제, 포스포디에스테라제 억제제, 복합제 등으로 세분화됩니다. 항콜린제 세그먼트는 장기 작용형과 단기 작용형 모두 사용 가능하여 수요가 높기 때문에 가장 큰 시장 점유율을 차지합니다. 항콜린제는 기도와 비강에서 아세틸콜린의 작용을 억제함으로써 효과를 나타냅니다. 항콜린성 기관지 확장제는 콜린성 신경의 작용을 방해하여 근육을 이완시키고 기도를 확장시킵니다. 아트라벤트 HFA(이프라트로피움)와 스피리바 레스피맷(티오트로피움)은 가장 일반적으로 사용되는 항콜린성 기관지 확장제입니다. 아트라벤트 HFA(이프라트로피움)는 정량 흡입기와 네뷸라이저 용액으로 제공되며, 스피리바 레스피맷(티오트로피움)은 건조 분말 흡입기입니다.
포스포디에스테라제 억제제 부문은 예측 기간 동안 긍정적인 시장 성장을 견인할 것으로 예상됩니다. 포스포디에스테라제 억제제는 세포 내 cAMP(cyclic adenosine monophosphate) 수치를 증가시켜 기관지 확장을 유도합니다. 이러한 억제제는 횡격막 근육 수축력을 개선하고 호흡 중추를 자극하는 데 효과적입니다.
또한, 시장은 작용 방식에 따라 장기 작용 기관지 확장제와 단기 작용 기관지 확장제로 분류됩니다. 장기 작용 기관지 확장제 부문은 천식 및 COPD 환자의 호흡곤란 조절에 장기 작용 기관지 확장제가 더 많이 사용됨에 따라 가장 높은 시장 점유율을 차지하고 있습니다. 장기 작용 기관지 확장제는 천식 환자에서 코르티코스테로이드의 효능을 높이는 데 효과적입니다. 이 시장은 애드베어(Advair), 듀레라(Dulera) 및 심비코트(Symbicort, 베타 효능제 기관지 확장제와 흡입 스테로이드의 복합제), 세레벤트(Serevent, 살메테롤), 포라딜(Foradil, 포르모테롤), 퍼포로미스트(Perforomist, 네뷸라이저용 포르모테롤 용액) 등을 포함한 장기 작용 기관지 확장제가 주도하고 있습니다. 세레벤트 디스커스(Serevent Diskus)는 천식 발작이나 운동 유발성 기관지 경련 예방에 사용됩니다. 또한 폐기종 및 만성 기관지염을 포함한 만성 폐쇄성 폐질환(COPD) 치료에도 사용됩니다.
단기 작용 기관지 확장제 부문은 예측 기간 동안 긍정적인 시장 성장을 보일 것으로 예상됩니다. 단기 작용 기관지 확장제는 천명, 호흡 곤란, 가슴 답답함과 같은 갑작스러운 증상을 치료하는 데 사용됩니다. 이러한 기관지 확장제는 신속 작용 기관지 확장제인 알부테롤, 레발부테롤, 피르부테롤이며, 이들은 시중에 나와 있는 속효성 기관지 확장제입니다. 이 기관지 확장제들은 기도를 확장시켜 급성 천식 증상이나 발작을 매우 빠르게 완화시켜 줍니다. 속효성 기관지 확장제는 천식 환자 치료에 효과적입니다.
세계 기관지 확장제 시장 - 지역별 분석
북미 지역은 세계 기관지 확장제 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
지역별로 기관지 확장제 시장은 북미, 남미, 유럽, 아시아 태평양, 중동 및 아프리카로 구분됩니다. 모든 지역 중 북미는 만성 폐쇄성 폐질환(COPD)과 천식의 높은 유병률로 인해 기관지 확장제 시장을 주도하고 있습니다. 미국 질병예방 및 건강증진국(ODPHP)에 따르면 2020년 미국에서는 약 1,480만 명의 성인이 만성 폐쇄성 폐질환(COPD)을 앓고 있으며, 2,500만 명이 천식을 앓고 있습니다. 만성 폐쇄성 폐질환(COPD)의 유병률은 대기 오염 물질 노출 증가, 유전적 요인, 호흡기 감염 등으로 인해 증가하고 있습니다. 기관지 확장제 개발 분야에서는 기술 발전이 활발히 이루어지고 있으며, 기관지 확장제 연구 개발에 대한 높은 투자가 시장 성장을 촉진할 것으로 예상됩니다.
아시아 태평양 지역은 개발 중인 기관지 확장제의 수가 증가하고 기관지 확장제의 공급이 늘어남에 따라 긍정적인 시장 성장을 보일 것으로 전망됩니다. 특히 흡연 인구 비율이 높고 담배 생산국이 많은 중국은 COPD와 천식 발병 위험을 높이는 요인으로 인해 가장 높은 시장 성장률을 기록할 것으로 예상됩니다. 기관지 확장제 사용에 대한 인식이 높아짐에 따라 예측 기간 동안 시장 성장이 촉진될 것입니다.
글로벌 기관지 확장제 시장 - 경쟁 환경
기관지 확장제 시장은 여러 국제 및 지역 시장이 존재하여 경쟁이 매우 치열합니다. Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Sanofi는 상당한 시장 점유율을 보유한 주요 시장 참여자입니다.
기업들은 시장에서의 입지를 유지하기 위해 신제품 승인, 신제품 개발, 시장 확장 및 제품 다각화 전략을 활용하고 있습니다.
또한 기업들은 기관지 확장제에 대한 수요를 늘리고 전 세계적으로 사업을 확장하기 위해 협력, 합병, 전략적 제휴 및 인수를 진행하고 있습니다. 예를 들어, 2019년 6월 Theravance Biopharma와 Mylan은 Yupelri(Revefenacin) 개발 및 상용화 계약을 중국 및 인접 지역으로 확대했습니다.
글로벌 기관지 확장제 시장 – 주목해야 할 주요 기업
Abbott Laboratories:
개요: Abbott는 의료기기 및 헬스케어 제품을 개발하는 미국의 다국적 기업입니다. 1888년에 설립되었으며 미국 일리노이주에 본사를 두고 있습니다. 제품 및 서비스에는 의료기기, 진단, 영양 제품 및 브랜드 제네릭 의약품이 포함됩니다.
제품 포트폴리오:
Leutrol: 천식 치료에 사용되는 약물입니다. 에이코사노이드 합성 경로의 5-리폭시게나제 효소를 억제하여 류코트리엔 합성을 차단합니다.
주요 개발: 2020년 10월, Abbott는 FDA로부터 COVID-19 IgM 항체 혈액 검사에 대한 긴급 사용 승인을 받았습니다.
이 글로벌 기관지 확장제 시장 보고서는 약 1,000개의 기업에 대한 정보를 제공합니다. 45개 이상의 시장 데이터 표, 40개 이상의 그림, 180페이지 분량.

보고서 요약(영어 원문)

Global Bronchodilators Market Overview
The global bronchodilators Market size was valued US$ 42,649.87 million in 2022 and is estimated to reach US$ 66,314 million by 2030, growing at a CAGR of 5.9% during the forecast period (2023-2030).
Bronchodilators are the medications used for relaxing the muscles by opening the airways or widening the bronchial tubes in the lungs. These medications allow the air to move in and out of the lungs. Bronchodilators are effective in reducing the mucus from the lungs. These drugs are used to treat long-term conditions including asthma, and chronic obstructive pulmonary disease (COPD).
Global Bronchodilators Market- Dynamics
The bronchodilators market is driven by the rising prevalence of chronic obstructive pulmonary disease (COPD) and Asthma owing to the changing lifestyle, including smoking, tobacco consumption, and others.
Increasing advancements in technology and rising prevalence of chronic obstructive pulmonary disease are expected to drive market growth.
The bronchodilators market is driven by the rising prevalence of chronic obstructive pulmonary disease (COPD) and Asthma owing to the changing lifestyle, including smoking, tobacco consumption, and others. Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease that causes breathlessness and predisposes to exacerbations and serious illness. According to the World Health Organization (WHO) in 2019, around 251 million people suffer from Chronic obstructive pulmonary disease (COPD) worldwide. Around 3.23 million people died due to Chronic obstructive pulmonary disease (COPD) worldwide.
The rise in the number of approvals of novel bronchodilators shall stimulate market growth. In April 2019, Circassia had received approval for its medication Duaklir to maintain chronic obstructive pulmonary disease (COPD). Duaklir is a combination of two long-acting bronchodilators, i.e., aclidinium bromide (400 mcg) and formoterol fumarate (12 mcg).
The increase in the research and development activities for the development of bronchodilators. The expected launch of the novel products shall stimulate market growth. For instance, Verona Pharma plc is developing the first-in-class development candidate, i.e., ensifentrine, an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, a bronchodilator and an anti-inflammatory agent in a single compound. However, adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.
Adverse effects associated with bronchodilators is expected to hamper the market growth.
Adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.
Global Bronchodilators Market - Industry Analysis
The global bronchodilators Market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.
Global Bronchodilators Market - Segment Analysis
Drug type segment is expected to hold the largest market share in global bronchodilators market
The bronchodilators market is segmented based on the drug type: sympathomimetics, anticholinergics, a phosphodiesterase inhibitor, combination drugs, etc. The anticholinergics segment accounts for the highest market share owing to the higher uptake of anticholinergics as it is available in both long-acting and short-acting forms. The anticholinergics act by inhibiting the effect of acetylcholine on airways and nasal passages. The anticholinergics bronchodilators hamper cholinergic nerves' effect and lead the muscles to relax and dilate the airways. Atrovent HFA (ipratropium) and Spiriva Respimat (tiotropium) are the most commonly used anticholinergic bronchodilators. Atrovent HFA (ipratropium) is available as a metered-dose inhaler, and nebulizer solution and Spiriva Respimat (tiotropium) is a dry powder inhaler.
The phosphodiesterase inhibitor segment accounts for the positive market growth over the forecasted period. The phosphodiesterase inhibitor results in bronchodilation by increasing the intracellular cyclic adenosine monophosphate (cAMP). These inhibitors are effective in improving the diaphragm muscle contractility and stimulate the respiratory centre.
Further, the market is also classified based on the mode of action as long-acting bronchodilators and short-acting bronchodilators. The long-acting bronchodilators segment accounts for the highest market share due to the higher adoption of long-acting bronchodilators for controlling breathlessness among people with asthma and COPD. Long-acting bronchodilators are effective in increasing the efficacy of corticosteroids among patients with asthma. The market is dominated by the availability of long-acting bronchodilators, including the Advair, Dulera & Symbicort (a combination of a beta-agonist bronchodilator and an inhaled steroid), Serevent (salmeterol), Foradil (formoterol), Perforomist (formoterol solution for nebulizers), and others. The Serevent Diskus is used for the prevention of asthma attacks or exercise-induced bronchospasm. It is also used to treat chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.
The short-acting bronchodilators segment is expected to have positive market growth over the forecasted period. Short-acting bronchodilators are used to treat sudden symptoms, including wheezing, shortness of breath, and chest tightness. These bronchodilators are the quick, active Albuterol, levalbuterol, and pirbuterol are the short-acting bronchodilators present in the market. These bronchodilators relieve acute asthma symptoms or attacks very quickly by opening airways. Short-acting bronchodilators are effective for the treatment of patients with asthma.
Global Bronchodilators Market - Geographical Analysis
North America region holds the largest market share in the global bronchodilators market
By region, the bronchodilators market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all the regions, North America dominated the bronchodilators market due to the high prevalence of chronic obstructive pulmonary disease (COPD) and Asthma. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults suffer from the chronic obstructive pulmonary disease (COPD) in the United States in 2020. And 25 million are suffering from asthma. The prevalence of chronic obstructive pulmonary disease (COPD) increases with rising exposure to air pollutants, genetic factors, and respiratory infections. The market is witnessing technological advancement in the development of bronchodilators. The high investment in the research and development activities for bronchodilators shall stimulate market growth.
The Asia Pacific region is expected to have positive market growth due to the increasing number of developing bronchodilators. There is an increase in the availability of bronchodilators. China is expected to have the highest market growth due to a high proportion of the smoking population and tobacco producers. These factors increase the risk of developing the chronic obstructive pulmonary disease (COPD) and Asthma. The growing awareness regarding the use of bronchodilators shall fuel the market growth over the forecasted period.
Global Bronchodilators Market - Competitive Landscape
The bronchodilators market is highly competitive with the presence of several international and local markets. Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc, and Sanofi are the leading market players with significant market share.
Companies are using novel product approvals, new product development, market expansion, and product diversification strategies for holding their position in the market.
The companies enter into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for bronchodilators and their expansion across the globe. For instance, in June 2019, Theravance Biopharma and Mylan had expanded the Yupelri (Revefenacin) development and commercialization agreement to include China and adjacent territories.
Global Bronchodilators Market – Key Companies to Watch
Abbott Laboratories:
Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.
Product Portfolio:
Leutrol: It is a drug used for asthma. It inhibits 5-lipoxygenase enzyme from eicosanoid synthesis pathway which blocks synthesis of leukotriene.
Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.
The global bronchodilators market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. Rising prevalence concerning Lyme disease
4.1.1.2. Growing Technological Advancement
4.1.2. Restraints:
4.1.2.1. Adverse effects associated with bronchodilators
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Regulatory Analysis
5.3 Supply Chain Analysis
5.4 Pricing Analysis
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Sympathomimetics
6.2.1. Introduction
6.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
6.3. Anticholinergics
6.4. Phosphodiesterase Inhibitor
6.5. Combination Drugs
6.6. Others
7. By Mode of Action
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
7.1.2. Market Attractiveness Index, By Mode of Action
7.2. Long-Acting Bronchodilators
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Short-Acting Bronchodilators
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Asthma
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Chronic obstructive pulmonary disease (COPD)
8.4. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral
9.2.1. Introduction
9.2.2. Market Size Analysis, USD Mn and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Injection
9.4. Inhalers
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. The U.K.
10.3.7.3. France
10.3.7.4. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. Australia
10.5.7.5. Rest of Asia Pacific
10.6. The Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Form Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AstraZeneca plc.
12.3. Boehringer Ingelheim International GmbH
12.4. GlaxoSmithKline Plc.
12.5. F. Hoffmann-La Roche Ltd.
12.6. Novartis AG.
12.7. Pfizer Inc.
12.8. Sanofi
12.9. Teva Pharmaceutical Industries Ltd.
12.10. Vectura Group Plc.
LIST NOT EXHAUSTIVE
13. Global Bronchodilators Market – DataM
13.1. Appendix
13.2. About Us and End User
13.3. Contact Us

언급된 주요 기업들

Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Vectura Group Plc.

표 목록 (Tables)

List of Tables

Table 1 Global Bronchodilators Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Bronchodilators Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Bronchodilators Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Bronchodilators Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Bronchodilators Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Bronchodilators Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Bronchodilators Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 8 Global Bronchodilators Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Bronchodilators Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 10 Global Bronchodilators Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)

Table 11 Global Bronchodilators Market Value, By Indication, 2022-2033 (US$ Billion)

Table 12 Global Bronchodilators Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 13 Global Bronchodilators Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 14 Global Bronchodilators Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 15 Global Bronchodilators Market Value, By Region, 2022-2033 (US$ Billion)

Table 16 North America Bronchodilators Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 17 North America Bronchodilators Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 18 North America Bronchodilators Market Value, By Indication, 2022-2033 (US$ Billion)

Table 19 North America Bronchodilators Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 North America Bronchodilators Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Europe Bronchodilators Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 22 Europe Bronchodilators Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 23 Europe Bronchodilators Market Value, By Indication, 2022-2033 (US$ Billion)

Table 24 Europe Bronchodilators Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 25 Europe Bronchodilators Market Value, By Country, 2022-2033 (US$ Billion)

Table 26 Asia-Pacific Bronchodilators Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 27 Asia-Pacific Bronchodilators Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 28 Asia-Pacific Bronchodilators Market Value, By Indication, 2022-2033 (US$ Billion)

Table 29 Asia-Pacific Bronchodilators Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 30 Asia-Pacific Bronchodilators Market Value, By Country, 2022-2033 (US$ Billion)

Table 31 South America Bronchodilators Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 32 South America Bronchodilators Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 33 South America Bronchodilators Market Value, By Indication, 2022-2033 (US$ Billion)

Table 34 South America Bronchodilators Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 35 South America Bronchodilators Market Value, By Country, 2022-2033 (US$ Billion)

Table 36 Middle East and Africa Bronchodilators Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 37 Middle East and Africa Bronchodilators Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 38 Middle East and Africa Bronchodilators Market Value, By Indication, 2022-2033 (US$ Billion)

Table 39 Middle East and Africa Bronchodilators Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 40 Middle East and Africa Bronchodilators Market Value, By Country, 2022-2033 (US$ Billion)

Table 41 GlaxoSmithKline (GSK): Overview

Table 42 GlaxoSmithKline (GSK): Product Portfolio

Table 43 GlaxoSmithKline (GSK): Key Developments

Table 44 AstraZeneca: Overview

Table 45 AstraZeneca: Product Portfolio

Table 46 AstraZeneca: Key Developments

Table 47 Novartis: Overview

Table 48 Novartis: Product Portfolio

Table 49 Novartis: Key Developments

Table 50 Boehringer Ingelheim: Overview

Table 51 Boehringer Ingelheim: Product Portfolio

Table 52 Boehringer Ingelheim: Key Developments

Table 53 Teva Pharmaceuticals: Overview

Table 54 Teva Pharmaceuticals: Product Portfolio

Table 55 Teva Pharmaceuticals: Key Developments

Table 56 Sunovion Pharmaceuticals: Overview

Table 57 Sunovion Pharmaceuticals: Product Portfolio

Table 58 Sunovion Pharmaceuticals: Key Developments

Table 59 Viatris: Overview

Table 60 Viatris: Product Portfolio

Table 61 Viatris: Key Developments

Table 62 Cipla: Overview

Table 63 Cipla: Product Portfolio

Table 64 Cipla: Key Developments

Table 65 Lupin : Overview

Table 66 Lupin : Product Portfolio

Table 67 Lupin : Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Bronchodilators Market Share, By Drug Class, 2024 & 2033 (%)

Figure 3 Global Bronchodilators Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 4 Global Bronchodilators Market Share, By Indication, 2024 & 2033 (%)

Figure 5 Global Bronchodilators Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 6 Global Bronchodilators Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Bronchodilators Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 8 Beta 2 Adrenergic Agonists Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 9 Anticholinergics Drugs Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 10 Phosphodiesterase Inhibitors Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 11 Others Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 12 Global Bronchodilators Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 13 Oral Route of Administration in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 14 Injection Route of Administration in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 15 Inhalation Route of Administration in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 16 Global Bronchodilators Market Y-o-Y Growth, By Indication, 2023-2033 (%)

Figure 17 Asthma Indication in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 18 Chronic Obstructive Pulmonary Disease (COPD) Indication in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 19 Others Indication in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 20 Global Bronchodilators Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 22 Retail Pharmacies Distribution Channel in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 23 Online Pharmacies Distribution Channel in Global Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 24 Global Bronchodilators Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 25 North America Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 26 North America Bronchodilators Market Share, By Drug Class, 2024 & 2033 (%)

Figure 27 North America Bronchodilators Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 28 North America Bronchodilators Market Share, By Indication, 2024 & 2033 (%)

Figure 29 North America Bronchodilators Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 30 North America Bronchodilators Market Share, By Country, 2024 & 2033 (%)

Figure 31 Europe Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 32 Europe Bronchodilators Market Share, By Drug Class, 2024 & 2033 (%)

Figure 33 Europe Bronchodilators Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 34 Europe Bronchodilators Market Share, By Indication, 2024 & 2033 (%)

Figure 35 Europe Bronchodilators Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 36 Europe Bronchodilators Market Share, By Country, 2024 & 2033 (%)

Figure 37 Asia-Pacific Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 38 Asia-Pacific Bronchodilators Market Share, By Drug Class, 2024 & 2033 (%)

Figure 39 Asia-Pacific Bronchodilators Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 40 Asia-Pacific Bronchodilators Market Share, By Indication, 2024 & 2033 (%)

Figure 41 Asia-Pacific Bronchodilators Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 42 Asia-Pacific Bronchodilators Market Share, By Country, 2024 & 2033 (%)

Figure 43 South America Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 44 South America Bronchodilators Market Share, By Drug Class, 2024 & 2033 (%)

Figure 45 South America Bronchodilators Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 46 South America Bronchodilators Market Share, By Indication, 2024 & 2033 (%)

Figure 47 South America Bronchodilators Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 48 South America Bronchodilators Market Share, By Country, 2024 & 2033 (%)

Figure 49 Middle East and Africa Bronchodilators Market Value, 2022-2033 (US$ Billion)

Figure 50 Middle East and Africa Bronchodilators Market Share, By Drug Class, 2024 & 2033 (%)

Figure 51 Middle East and Africa Bronchodilators Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 52 Middle East and Africa Bronchodilators Market Share, By Indication, 2024 & 2033 (%)

Figure 53 Middle East and Africa Bronchodilators Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 54 GlaxoSmithKline (GSK): Financials

Figure 55 AstraZeneca: Financials

Figure 56 Novartis: Financials

Figure 57 Boehringer Ingelheim: Financials

Figure 58 Teva Pharmaceuticals: Financials

Figure 59 Sunovion Pharmaceuticals: Financials

Figure 60 Viatris: Financials

Figure 61 Cipla: Financials

Figure 62 Lupin : Financials